Trial Profile
A Proof-of-Concept Study for Ilorasertib (ABT-348) Activity in Patients With CDKN2A-Deficient Advanced Solid Cancers: a Phase II Basket Trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2023
Price :
$35
*
At a glance
- Drugs Ilorasertib (Primary)
- Indications Solid tumours
- Focus Proof of concept; Therapeutic Use
- 19 Jul 2023 Status changed from completed to discontinued.
- 27 May 2022 Status changed from active, no longer recruiting to completed.
- 04 May 2018 Status changed from recruiting to active, no longer recruiting.